Update, November 20, 2026
Since the November 6 report, JPMorgan Funds – US Value Fund C (acc) has slipped to $68.39, a 2.09% decline over the past five days while the S&P 500 fell 5.45% in the same period, keeping the stock ahead of the broader market.
The picture holds – the price remains above the 50‑day SMA at $67.97 and well above the swing‑zone support at $65.88, but it has not yet cleared the upside breakout threshold of $68.92 on volume, so the bullish bias for the next 2‑6 weeks stays intact. What would change the picture would be a weekly close below the $65.88 swing‑zone or a daily close above $68.92 with volume above the 20‑day average.
Recent macro headlines, such as the hedge‑fund losses in Brazil reported by Bloomberg Business, have not materially impacted the fund’s relative strength, which still outperforms the S&P 500 by about 5% on a 50‑day basis.
Update, November 13, 2026
Since the November 6 update the fund’s price has edged to $70.15, up 0.43% on the day but still down 0.48% over the past five days, while the S&P 500 fell 0.36% daily and rose 2.59% over the same five‑day span, keeping the stock’s relative strength intact.
The picture holds: the price remains above the key support at $70.0 and the stop at $69.87, but it has not yet broken the upside trigger of a daily close above $70.49 on volume above the 20‑day average. The next watch‑point is a weekly close below the swing‑zone at $65.88, which would change the picture.
Momentum indicators stay bullish – the 50‑day SMA sits at $67.89, the 200‑day SMA at $64.82 and the RSI is 61.5 – and the stock still leads the S&P 500 by about 4.3% over 50 days. No new earnings or sector shifts have emerged, and the recent macro headlines – such as the Brazil hedge‑fund losses reported by Bloomberg Business – have not materially impacted the fund’s trajectory. Absent a weekly close under $65.88, the bullish outlook for the next 2‑6 weeks remains unchanged.
Update, November 9, 2026
Since the November 6 report, JPMorgan Funds – US Value Fund C (acc) slipped to $68.52, down 2.79% on the day and 0.77% over the past five days, while the S&P 500 rose 2.64% and 0.34% respectively, indicating the stock underperformed the broader market.
The picture holds: the price remains above the 50‑day SMA at $67.78, keeping the bullish framework intact. The breakout level at a round $70 and the target at the 52‑week high $70.49 are still untouched, and the stop at $67.67 (derived from $67.78 minus a quarter‑ATR) remains below the current price. A weekly close below the swing‑zone support at $65.88 would be what would change the picture.
Recent macro headlines, such as the Brazilian hedge‑fund losses reported by Bloomberg Business, have not materially shifted the fund’s technical outlook.
JPMorgan Funds - US Value Fund C (acc) - USD (0P00000Z22) closed at $70.49 on November 6, 2026, up 1.95% over the last five days while the S&P 500 fell 2.70%. The stock is trading at its 52-week high, above its 50-day and 200-day averages, and the weekly trend remains up. The balance of evidence leans positive for the next 2–6 weeks, but conviction is medium because the stock needs a volume-backed close above $80.0 to confirm a breakout, and the current reward-to-risk from that level does not meet the 3-to-1 threshold.
Why it matters
The stock's resilience stands out against a weak tape. Over the past five days, 0P00000Z22 gained 1.95% while SPY dropped 2.70%, a relative outperformance of more than four percentage points. This is not a market-driven move; it is stock-specific strength. The 50-day relative performance versus SPY is +8.7%, and the 200-day relative performance is +8.6%, showing that the stock has been leading for months, not just days. The stock is up 19.5% year-to-date versus SPY's 7.8%, and it sits at its 52-week high of $70.49, 26.4% above its 52-week low of $55.75.
The backdrop is mixed. Financial Times reported on October 31 that investors are trimming growth bets over fears of the US economy's AI exposure, with the 10-year Treasury inflation-protected yield falling to 2.58%. Financial Times also noted that US midterms loom over jittery investors, with the S&P 500 roughly flat since July and cracks emerging in the AI trade. Morningstar reported that the US Total Market Index fell 0.42% for the week ended October 30, with healthcare and utilities leading while communication services and technology lagged. None of this directly explains 0P00000Z22's strength, but it suggests the stock is not relying on a rising tide.
The debate around the stock is constructive. CNBC on October 29 highlighted Microsoft's strong quarter, with revenue up 19% and Azure up 48%, and raised its price target to $580. Morningstar on October 22 praised American Funds Smallcap World as a great option for global small caps. Forbes on October 21 listed eight value stocks to buy for November, and Morningstar on October 20 highlighted ExxonMobil, Johnson & Johnson, and JPMorgan Chase as value stocks with moats. The bearish side is less visible in the news flow, but the market backdrop of AI-related jitters and midterm uncertainty is a real overhang. The stock's relative strength suggests it is being bid for its own merits, not as part of a broad risk rally.
There is no analyst consensus or price target data available for 0P00000Z22, so valuation against the analyst spread cannot be assessed. The stock's price action is the primary evidence: it is at a 52-week high, above its 50-day average of $67.79 and its 200-day average of $64.59, and the 14-day RSI is 72.55, which is overbought but not extreme. The stock is not cheap on a momentum basis, but the trend is clear.
What the evidence says
The long-term thesis is intact. The stock is above its 40-week average, and the daily trend runs with the weekly uptrend. The stock is in a mature phase of an uptrend, having risen 26.4% from its 52-week low, but it has not yet broken out to new highs beyond its current level. The 50-day and 200-day averages are both rising, and the stock is above both, confirming the trend. The thesis is not weakened; it is waiting for confirmation of the next leg.
For the next 2–6 weeks, the balance of evidence leans positive. The stock is leading the S&P 500 by 8.7% over 50 days, and it has held above the $70.0 round level despite a weak market. The conviction is medium, with 2 of 4 conviction points: the daily trend aligns with the weekly uptrend, and the stock is outperforming the S&P 500. The strongest case against the positive reading is that the stock is overbought (RSI 72.55) and the market is under pressure, with SPY down 5.4% over the past month. A pullback to the 50-day average at $67.79 would be a normal correction, and a weekly close below $65.88 would end the trend. But the stock has not shown signs of distribution, and the relative strength argues that buyers are in control. The medium conviction reflects that the stock needs a volume-backed breakout to $80.0 to confirm the next leg, and that has not happened yet.
Levels that matter
The structure holds above $70.0, a round number that has acted as support. The first crack below that is $70.0, and the trend would end below $65.88, a swing zone. The 50-day average at $67.79 and the 200-day average at $64.59 are secondary supports. A weekly close below $65.88 would signal that the uptrend is broken, and the next support would be $63.70, another swing zone.
The breakout level is a daily close above $80.0 on volume above its 20-day average. From $80.0, the target is $90.0, a round number, giving a reward of $10.0. The stop would be $69.91, based on $70.0 minus a quarter of the ATR (0.36), giving a risk of $10.09. The reward-to-risk is 1.0 to 1, which does not meet the 3-to-1 threshold that makes a breakout worth the risk. To reach 3-to-1, the target would need to be near $110, or the stop would need to be much tighter, but the stop is already tight relative to the ATR. The math does not favor a breakout trade at current levels, but the stock does not need a breakout to continue trending; it can grind higher from here.
What would change the picture
The picture would change on a weekly close below $65.88, a swing zone. That would break the uptrend and shift the balance of evidence negative. The one non-price fact that would change the picture is a negative earnings surprise or a significant deterioration in the company's fundamentals, but there is no earnings date or analyst data available. The market backdrop of AI-related jitters and midterm uncertainty is a risk, but it has not yet affected the stock's relative strength.
What to watch
- Next earnings date: not available; watch for any revenue or margin guidance that would justify the stock's premium to the market.
- Sector and market events: the US midterms and any further weakness in AI-related tech spending could pressure the market, but the stock's relative strength suggests it may be insulated.
- Valuation: no analyst consensus or price target is available; the stock's price action, particularly its ability to hold above $70.0, is the key gauge.